Sildenafil Prevents Podocyte Injury via PPAR-γ–Mediated TRPC6 Inhibition
Ramon Sonneveld(Radboud University Nijmegen), Tom Nijenhuis(Radboud University Nijmegen), Joost G.J. Hoenderop(Radboud University Nijmegen), Henry Dijkman(Radboud University Nijmegen), Carole Hénique(Inserm), Johan van der Vlag(Radboud University Nijmegen), Pierre‐Louis Tharaux(Inserm), Andrea M. Isidori(Policlinico Umberto I), Jo H. M. Berden(Radboud University Nijmegen)
Cited by 67
Related Papers
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Complications of Cushing's syndrome: state of the art
|The Lancet Diabetes & Endocrinology|2016|602